175 related articles for article (PubMed ID: 21073062)
1. Immunogenicity of HBV vaccine during stated shelf-life.
Gloriani NG; Srinivasa K; Bock HL; Hoet B
Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
Raz R; Koren R; Bass D
Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
[TBL] [Abstract][Full Text] [Related]
4. Comparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene) in healthy adults.
Rebedea I; Diaconescu IG; Bach D; Bartelsen O; Arndtz N
Vaccine; 2006 Jun; 24(25):5320-6. PubMed ID: 16707195
[TBL] [Abstract][Full Text] [Related]
5. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
[TBL] [Abstract][Full Text] [Related]
8. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.
Heron L; Selnikova O; Moiseieva A; Van Damme P; van der Wielen M; Levie K; Hoet B; Stoffel M
Vaccine; 2007 Apr; 25(15):2817-22. PubMed ID: 17276552
[TBL] [Abstract][Full Text] [Related]
12. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates.
Jafarzadeh A; Zarei S; Shokri F
Vaccine; 2008 Jan; 26(2):269-76. PubMed ID: 18037544
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
[TBL] [Abstract][Full Text] [Related]
14. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
[TBL] [Abstract][Full Text] [Related]
15. [The immunogenicity and safety of 10 microg recombination yeast hepatitis B vaccine applied in expanded population].
Fu QP; He H; Li L; Chen HP; Zeng YX; Liu QL; Fang G; Dong CM; Guo SH; Li HG; Wang HY; He CS; Zhou SZ; Li L; Gu SN; Zhang ZF; Dai M
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Oct; 43(10):903-6. PubMed ID: 20137473
[TBL] [Abstract][Full Text] [Related]
16. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
[TBL] [Abstract][Full Text] [Related]
17. Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults.
Van Damme P; von Sonnenburg F; Hatz C; Hoet B; Lefevre I; Leyssen M
J Med Virol; 2009 Oct; 81(10):1710-5. PubMed ID: 19697416
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant.
Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R
Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents].
González-Huezo MS; Sánchez-Avila F; García Mayol M; Castro Narro G; Sixtos S; Lisker-Melman M; Kershenobich D
Rev Gastroenterol Mex; 2003; 68(4):271-6. PubMed ID: 15125329
[TBL] [Abstract][Full Text] [Related]
20. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule.
Connor BA; Blatter MM; Beran J; Zou B; Trofa AF
J Travel Med; 2007; 14(1):9-15. PubMed ID: 17241248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
